Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, has entered into an asset purchase agreement with Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species. BAL2062 (formerly GR-2397) is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., incl...